Company Overview

Dr. Lal PathLabs Limited submitted its Annual Report for FY 2025-26 in compliance with SEBI Listing Regulations, reporting strong financial performance and significant corporate actions.

Financial Performance Highlights

Consolidated Results: Revenue from operations grew 12.2% YoY to ₹27,629 million, with reported PAT of ₹5,098 million (3.6% growth). Normalized PAT excluding one-time items showed 17.9% growth to ₹5,323 million. ROCE (Excl. Cash & Investments) stood at 44%.

Standalone Results: Revenue increased 12.6% to ₹26,476 million with net profit of ₹5,082 million (2.5% growth). Other income contributed ₹1,127 million including interest income of ₹615 million and dividend income of ₹189 million.

Operational Metrics & Expansion

The company expanded its operational network to 312 clinical laboratories (+14 added during FY26) and 7,727 Patient Service Centres, serving 30.3 million patients and testing 94.5 million samples. Tier 3+ markets contributed 39% of revenue. The workforce exceeded 6,200 employees group-wide.

Corporate Actions & Capital Structure

Bonus Issue: Implemented 1:1 bonus share issue on December 22, 2025, issuing 83.78 million shares, increasing paid-up capital from ₹835.92 million to ₹1,675.55 million.

Dividends: Paid interim dividend of ₹16.50 per share and proposed final dividend of ₹4 per share, totaling ₹2,170 million payout for FY26. Previous dividends included final FY25 (₹6), and three interim FY26 payments (₹6, ₹7, ₹3.5).

Credit Rating: Upgraded to CARE AA+/Stable from CARE AA/Stable in March 2026, reflecting improved financial position.

Strategic Initiatives & Innovation

  • Launched AI-powered Sovaaka precision health screening platform
  • Hosted first international Medllumina conference on advanced diagnostics
  • Introduced 13 first-in-India diagnostic tests across oncology, neurology, immunology and molecular diagnostics
  • Implemented AI in cancer diagnostics, hematology, and antibiotic sensitivity reporting
  • Digital transformation initiatives across operations

Financial Position & Investments

Property, Plant & Equipment: Carrying amount ₹3,097 million with major additions in freehold buildings (₹792 million) and plant equipment (₹469 million).

Goodwill & Intangibles: Carrying value of ₹5,482 million for goodwill (tested using 13.40% discount rate) and ₹1,915 million for other intangible assets with no impairments recognized.

Investments: Total investments of ₹4,226 million primarily in money market and liquid mutual funds.

ESG & Sustainability Performance

  • Solar capacity: 3.22 MW cumulative generation
  • CO2 emissions eliminated: 2,515 MT
  • Water saved through RO recycling: 9,125 KL
  • CSR spend: ₹102.2 million benefiting 9.2 million people
  • Phlebotomist training: 3,100 certified through LPL Academy

Significant Accounting Items

Labour Code Impact: Recognized ₹301 million exceptional item for new Labour Code implementation, including ₹258 million gratuity liability increase and ₹43 million leave liability impact.

Employee Benefits: Gratuity liability stood at ₹958.53 million with plan assets of ₹397 million, resulting in net liability of ₹562 million.

Subsidiaries & Business Combinations

Completed voluntary liquidation of Suburban Diagnostics (India) Private Limited, transferring business undertaking to the company with capital reserve of ₹681 million. Consolidated subsidiaries include Dr. Lal PathLabs Nepal, Bangladesh operations, and several Indian diagnostic entities.

Governance & Compliance

Board Composition: 9 directors (2 executive, 2 non-executive, 5 independent) with appropriate committee meetings conducted.

Regulatory Compliance: Full compliance with SEBI Listing Regulations, no material orders from regulators/courts, and operational whistleblower mechanism.

Auditors: Deloitte Haskins & Sells LLP as statutory auditors, Chandrasekaran Associates as secretarial auditors, and A.G. Agarwal & Associates recommended for cost audit.

Forward Outlook

The company maintains strong growth trajectory with continued expansion in tier 3+ markets, digital innovation, and diagnostic capabilities enhancement. All forward-looking statements are subject to regulatory risks and market conditions.